Detalhe da pesquisa
1.
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Br J Haematol
; 204(5): 1838-1843, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38471524
2.
Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience.
Transfusion
; 62(11): 2363-2369, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151933
3.
Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Ann Hematol
; 97(8): 1349-1356, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572561
4.
Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Cancer Res Commun
; 4(2): 365-377, 2024 02 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300528
5.
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Lancet Haematol
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38824932
6.
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
Elife
; 122023 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36629404
7.
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
Leuk Lymphoma
; 63(5): 1227-1235, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969346
8.
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
Ther Adv Hematol
; 13: 20406207221127547, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36199837
9.
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes.
Nat Commun
; 13(1): 7619, 2022 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36494342
10.
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Leuk Lymphoma
; 60(6): 1522-1527, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30499738